Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Amortizatization of Intangibles: 2020-2025

Historic Amortizatization of Intangibles for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $1.0 million.

  • Lyell Immunopharma's Amortizatization of Intangibles fell 71.87% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 54.54%. This contributed to the annual value of $14.7 million for FY2024, which is 52.99% up from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Amortizatization of Intangibles is $1.0 million, which was down 13.39% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Amortizatization of Intangibles registered a high of $4.4 million during Q1 2024, and its lowest value of -$552,000 during Q3 2021.
  • In the last 3 years, Lyell Immunopharma's Amortizatization of Intangibles had a median value of $2.3 million in 2023 and averaged $2.6 million.
  • In the last 5 years, Lyell Immunopharma's Amortizatization of Intangibles crashed by 198.38% in 2021 and then soared by 998.27% in 2023.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Amortizatization of Intangibles stood at -$467,000 in 2021, then spiked by 358.67% to $1.2 million in 2022, then skyrocketed by 180.13% to $3.4 million in 2023, then dropped by 12.38% to $3.0 million in 2024, then slumped by 71.87% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.2 million for Q2 2025, and $1.7 million during Q1 2025.